PTGS2 and cardiovascular disorder: A previous study shows that coxibs and tNSAIDs, acting as an anti-inflammatory through the inhibition of the COX-2 enzyme, are associated with an increased risk of cardiovascular disease and upper gastrointestinal complications [30].